Charles River Laboratories Announces Second-Quarter 2024 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
JPMorgan Downgrades Charles River Labs (CRL) to Neutral
August 8, 2024 5:55 AM EDTJPMorgan analyst Tycho W. Peterson downgraded Charles River Labs (NYSE: CRL) from Overweight to Neutral with a price target of $205.00 (from $270.00).
The analyst comments "As we noted yesterday in our first take, CRL reported a 2Q top- and bottom-line beat (with the latter aided by $0.30 worth of lower bonus accrual benefit) but took down guidance substantially due to an unexpectedly weaker demand environment in DSA. While buyside expectations assumed a guide cut to 2H24 on a slower pace of recovery in biotech within DSA, the magnitude... More
